Momenta Pharmaceuticals Inc. Stock Upgraded (MNTA)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Momenta Pharmaceuticals (Nasdaq: MNTA) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • MNTA has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 18.11, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to where it was 12 months ago, the stock is up, but it has so far lagged the appreciation in the S&P 500. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • MNTA, with its very weak revenue results, has greatly underperformed against the industry average of 8.7%. Since the same quarter one year prior, revenues plummeted by 80.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$20.75 million or 223.07% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. Momenta has a market cap of $760.2 million and is part of the health care sector and drugs industry. Shares are up 23.3% year to date as of the close of trading on Monday.

You can view the full Momenta Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Teva Must Clear Three Big Hurdles to Reclaim Its Perch

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Sarepta Leads Biotech Movers on Voucher Deal News